Back to search results

BMT-CARE: Psychosocial Support for Transplant Caregivers

This study, called BMT-CARE, is testing a support program for caregivers of patients undergoing a hematopoietic cell transplant (HCT), also known as a bone marrow transplant. The program, BMT-CARE, involves 6 sessions with a therapist. Researchers want to see if BMT-CARE improves the quality of life for caregivers compared to usual care, which includes meeting a social worker. You may be eligible if you are an adult caregiver (18 years or older) of a patient receiving an HCT for cancer, live with them or see them often, and can read surveys in English or Spanish. The study aims to enroll about 800 participants (caregivers and patients).

Study design
This is a randomized clinical trial, meaning participants will be assigned by chance to either receive the BMT-CARE intervention or usual care. The study plans to enroll about 800 participants (400 caregivers and 400 patients).
What's involved
Participation in this study is expected to last up to 180 days after the patient's hematopoietic cell transplant (HCT). If in the BMT-CARE group, you will have 6 sessions with a therapist.
Compensation
Not stated in the trial record.
Follow-up
Caregiver quality of life will be measured up to 60 days after the patient's hematopoietic cell transplant (HCT).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06472089

BMT-CARE: Psychosocial Intervention for Transplant Caregivers

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~800 participants
Updated 2025-10-15 on ClinicalTrials.gov
What's tested:BMT-CAREUsual Care

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Caregiver quality of life (QOL) as measured by the Caregiver Oncology Quality of Life (CARGOQOL) questionnaire
Measured over Up to 60 days post-HCT

Conditions

Bone Marrow Transplant Complications
Hematologic Malignancy

Explore related trials

Malignant neoplasm of lymphoid, hematopoietic and/or related tissue

NCT06472089

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Moffitt Cancer Center

    Tampa, Floridastudy coordinator listed

    Recruiting

  • University of Alabama at Brimingham

    Birmingham, Alabamastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Areej El-Jawahri, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
  • Jamie Jacobs, PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Areej El-Jawahri, MD
[email protected]
617-721-4000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult caregivers (≥18 years) relative or friend of a patient identified as living with them or having in-person contact with them at least twice a week.
Caregiver of a patient receiving allogeneic or autologous HCT for the treatment of cancer.
Ability to read and respond to survey questions in English, Spanish or with minimal assistance from an interpreter.
Adult patients (≥18 years) with a hematologic malignancy and planned admission for autologous or allogeneic HCT.
Ability to respond to questions in English, Spanish, or with minimal assistance from an interpreter.

Exclusion

Caregivers of patients undergoing HCT for a benign hematologic condition or undergoing outpatient HCT.
Caregivers with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.
Caregivers of patients who have already undergone HCT within the past 5 years

What this trial measures

  • Caregiver quality of life (QOL) as measured by the Caregiver Oncology Quality of Life (CARGOQOL) questionnaireUp to 60 days post-HCT

    Compare caregiver QOL as measured by the CARGOQOL between the two study groups. The CARGOQOL ranges from 0-100 with higher scores indicating better QOL